Ɛp fɔ gɛt dayabitis ɛn fɔ lɛf fɔ it bɔku bɔku it? Lɛ wi lan bɔt GLP-1 Agonist dɛn insay wan simpul we

Yu gɛt Tayp 2 dayabitis? Ɔ yu de strɛs wit bɔku bɔdi wet (fat pasmak)? Dɔn yu dɔktɔ go dɔn tɛl yu bɔt wan nyu kayn mɛrɛsin we bɔku pipul dɛn de tɔk bɔt dɛn tɛm ya. So tide, lɛ wi tɔk bɔt dis klas ɔf drɔgs we dɛn kɔl GLP-1 agonist. Lɛ wi tɔk bɔt wetin na dɛn tin ya, aw dɛn de wok, ɛn udat dɛn fit fɔ.

Wetin na di GLP-1 agonist dɛn?

Fɔ tɔk am simpul wan, GLP-1 agonist na wan klas ɔf drɔgs we de ɛp fɔ kɔntrol di blɔd shuga (glukɔs) lɛvɛl, mɔ pan pipul dɛn we gɛt Tayp 2 dayabitis . Sɔm pan dɛn mɛrɛsin ya kin ɛp bak fɔ kɔntrol di fat, ɔ di bɔdi wet pasmak .

Bɔku pan dɛn mɛrɛsin ya kin kam as injɛkshɔn. Dis min se yu nid fɔ yuz sirinj ɛn nidul fɔ injɛkt wata we gɛt wata. dis injεkshכn de gi insay di fεt tisu dεm we de כnda di skin (sכbkutan injεkshכn). Dɛn kin gi dis injɛkshɔn na say dɛn we fat de na di bɛlɛ, di bak pat na di shɔl, di ɔp pat na di bɔdi, ɛn di bak pat na di an. I gɛt bak mɛrɛsin dɛn we dɛn kin it, lɛk Semaglutide tablɛt (Rybelsus®).

Dɛn kin kɔl dis grup fɔ drɔgs bak wit sɔm ɔda nem dɛn:

• Pεptida-1 agonist dεm we lεk glukagכn
• GLP-1 rεsεptכr agonist dεm
• Incretin mimɛtik dɛn

Dɛn mɛrɛsin ya na nyu tin dɛn. Di fɔs GLP-1 agonist (exenatide) bin apruv insay 2005. Risach pipul dɛn stil de fɛn ɔda we dɛn fɔ yuz dɛn drɔgs ya.

Aw dis mɛrɛsin de wok na di bɔdi?

Fɔ ɔndastand aw dis mɛrɛsin de wok, lɛ wi fɔs luk wan ɔmon we dɛn kin mek na wi bɔdi we dɛn kɔl GLP-1. GLP-1 na wan ɔmon we wi smɔl intestinal de mek. I de du bɔku tin dɛn na wi bɔdi.

• I de ɛp di pankrias fɔ pul insulin: Insulin na ɔmon we impɔtant fɔ chenj di it we wi de it to ɛnaji. I de mek di shuga we de na di blɔd nɔ bɔku. If insulin nɔ de, di shuga we de na di blɔd kin go ɔp ɛn dayabitis kin kam.
• Glucagon ɔmon de blok: Glucagon na ɔmon we de mek di blɔd shuga go ɔp we dɛn nid am. So, GLP-1 de blok dis, we de mek di shuga we nɔ nid nɔ de gɛda na di blɔd.
• I de slo di rit we di bɛlɛ de ɛmti: We di it we wi de it de dayjɛst ɛn ɛmti am na di bɛlɛ sloslo, di shuga we de kɔmɔt na di it de go insay di blɔd. Dis kin kɔntrol di shuga we de na di blɔd we kin go ɔp wantɛm wantɛm.
• If yu it, i de mek yu fil se yu ful-ɔp (satiety):Di GLP-1 ɔmon de afɛkt di pat dɛn na wi bren we de kɔntrol angri ɛn ful-ɔp.

naw, wetin dis GLP-1 agonist dכg de du na fכ bihayv εksakכt lεk di GLP-1 כmon na wi bכdi. Dat min se, i de wok ‘lɛk’ am. dis dכg de tay pan di GLP-1 rεsεpכta dεm εn i de mek di sem akshכn dεm we di nεchכral כmon de du. Di mɔ di doz fɔ di mɛrɛsin, na di mɔ dis ifɛkt go bɔku.

Udat dɛn kin se dɛn fɔ tek dis mɛrɛsin fɔ?

Dɔktɔ dɛn kin gi dɛn GLP-1 agonist mɛrɛsin ya fɔ tu kɔndishɔn dɛn: Tayp 2 dayabitis ɛn fɔ fat.

Fɔ Tayp 2 Dayabitis

Yu dɔktɔ kin gi yu GLP-1 agonist dɛn, we dɛn put am togɛda wit di men mɛrɛsin fɔ dayabitis (mɛtfɔmin), if i nɔ kɔntrol yu blɔd shuga fayn fayn wan, ɔ fɔ ɔda rizin dɛn. Speshal wan:

• If di blɔd shuga kɔntrol nɔ inof wit mɛtfɔmin nɔmɔ.
• If yu nɔ ebul fɔ tek metformin fɔ ɔda wɛlbɔdi rizin.
• If yu A1C lɛvɛl bɛtɛ pas di target.
• If yu gɛt dayabitis wit ɔda tin dɛm lɛk at sik, kɔnjɛstiv at fayl, ɔr kidni sik we nɔr de dɔn.

Fɔ Fat pasmak

GLP-1 agonist dεm lεk Semaglutide εn Liraglutide dεn dכn apruv dεm bak as tritmεnt fכ fat biכs dεn de εp fכ lכs wet. Dɛn kin difayn fɔ fat as bɔdi mas indeks (BMI) we gɛt 30 ɔ pas dat. Dɔktɔ dɛn kin gi dɛn mɛrɛsin ya bak to pipul dɛn we gɛt bɔku bɔku bɔdi (BMI 25-29.9) ɛn we gɛt ɔda wɛlbɔdi prɔblɛm (e.g., ay blɔd prɛshɔn, kɔlɔstrel), bikɔs fɔ lɛf fɔ it bɔku bɔku it kin ɛp fɔ kɔntrol dɛn tin dɛn de.

Pipul wae gɛt Tayp 1 dayabitis kin tek dɛn tin ya?

Dis stil de na di risach pat. Dɛn nɔ dɔn ɔfishal wan gri fɔ am yet as tritmɛnt fɔ Tayp 1 dayabitis. Bɔt sɔm dɔktɔ dɛn kin gi am "ɔf-lɛbul" as nid de. I bɛtɛ fɔ mek yu tɔk to yu dɔktɔ bɔt dis.

Lan bɔt aw fɔ yuz mɛrɛsin ɛn di bad tin dɛn we i kin du.

Yu dɔktɔ go disayd aw ɔltɛm yu fɔ tek dis mɛrɛsin. I rili impɔtant fɔ fala dɛn instrɔkshɔn dɛn de di rayt we.

Wetin na di bad tin dɛn we dis mɛrɛsin kin du?

Lɛk ɛni mɛrɛsin, dɛn tin ya kin gɛt bad bad tin dɛn.

• Kɔmɔn sayd ɛfɛkt dɛm: Dɛn kin si dɛn tin ya mɔs kwik kwik wan we dɛn de du di tritmɛnt.
• Fil fɔ it
• Vɔmit
• Fɔ vɔmit
• Rɔnbɛlɛ
• Ɔda bad tin dɛn we kin apin:
• Diziz we pɔsin kin gɛt
• Di at bit fast smɔl
• Ed de at
• Wan bɛlɛ we nɔ fayn
• Di sayd ɛfɛkt dɛn we nɔ kin apin so ɔltɛm bɔt we kin rili siriɔs:
• Pankriaytis we gɛt sik
• Wan kayn tayroyd kansa (Mɛdulari tayroyd kansa) .
• Akyu kidni injuri
• Di retinopathy we gɛt fɔ du wit dayabitis we de wɔs

Wetin na di prɔblɛm dɛn we dɛn mɛrɛsin ya kin gɛt?

Pan ɔl we bɔku tɛm dis mɛrɛsin nɔ bad, sɔm tin dɛn de we yu fɔ no bɔt.

Alɛji Riakshɔn dɛn

Sɔm pipul dɛn kin gɛt alɛji fɔ dis mɛrɛsin. If yu de it ɔ yu de rɛd ɔltɛm na di say we dɛn inj yu, tɛl yu dɔktɔ. Bɔt, wan bad bad alɛji we dɛn kɔl anafylaksis na imejensi.

Yuz am we yu gɛt bɛlɛ

GLP-1 agonist dεm nכ de rεkomεnd fכ yuz we uman bεlε . If yu de tek dis mɛrɛsin, yu fɔ yuz wan we we pɔsin kin abop pan fɔ kɔntrol di pikin. If yu gɛt bɛlɛ we yu de tek dis mɛrɛsin, go to yu dɔktɔ wantɛm wantɛm.

Lɔw blɔd shuga (Hypoglycemia) .

Di risk fɔ gɛt haypoglycemia nɔ bɔku we yu tek dis mɛrɛsin nɔmɔ. Bɔt if yu tek am wit ɔda mɛrɛsin fɔ dayabitis, lɛk insulin ɔ sulfonylureas, di risk fɔ mek yu gɛt ay blɔd blɔd. If yu blɔd shuga go dɔŋ pas 70 mg/dL, yu kin gɛt sɔm sayn dɛn lɛk fɔ shek, swet, diziz, ɛn angri pasmak. If dis apin, yu fɔ it sɔntin we gɛt shuga (lɛk drink we gɛt shuga, banana) kwik kwik wan.